Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
Posted:
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient survival — the gold standard outcome of any cancer study.
Wearable medical devices are changing healthcare delivery by shifting care beyond traditional settings and bringing it closer to patients’ daily lives. By offering continuous monitoring, promoting patient engagement and supporting remote interventions, these technologies are becoming an essential part of…
Attendees
Sponsors and Exhibitors
Agenda 2025
Contact us